A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis

ConclusionsTrials for people with ALS have neglected the importance of neuropsychiatric symptoms and cognitive impairment. Evaluation of these extra-motor features is essential to understanding the impact of candidate drugs on all symptoms of ALS.PROPSERO registrationCRD42020175612.

http://link.springer.com/10.1007/s00415-020-10203-z

Source: Journal of Neurology - September 9, 2020 Category: Neurology Source Type: research